| Scorecard |
|---|
|
5 / 5 Stars
|
|
Lipper
5
5
5
5
3
|
|
Zacks Investment Research
1
(Strong Buy)
|
|
Standard & Poor's
4 / 5 Stars
|
|
TheStreet.com
A-
(Buy)
|
Fund Holdings
Asset Allocation
| % Long | % Net | |
|---|---|---|
| Cash | 5.39 | 5.39 |
| Stocks | 75.72 | 75.72 |
| Bonds | 0.0 | 0.0 |
| Other | 0.36 | 0.36 |
| Foreign Bonds | 0.0 | 0.0 |
| Foreign Stocks | 18.49 | 18.49 |
| Convertible | 0.04 | 0.04 |
| Preferred | 0.0 | 0.0 |
Updated 03.31.2013
Top 10 Holdings
Performance as of 05.31.2013
Portfolio as of 03.31.2013
| Ticker | YTD Return % | % Net Assets | |
|---|---|---|---|
| Gilead Sciences Inc | GILD | 44.64 | 5.06 |
| Alexion Pharmaceuticals, Inc. | ALXN | 1.86 | 4.83 |
| Catamaran Corp | CTRX | 2.12 | 4.19 |
| Valeant Pharmaceuticals International Inc | VRX | 47.58 | 2.94 |
| Pharmacyclics, Inc. | PCYC | 52.8 | 2.73 |
| Incyte Corp Ltd | INCY | 31.91 | 1.98 |
| UnitedHealth Group Inc | UNH | 16.17 | 1.92 |
| Celgene Corporation | CELG | 54.06 | 1.66 |
| Regeneron Pharmaceuticals, Inc. | REGN | 38.0 | 1.63 |
| Onyx Pharmaceuticals, Inc. | ONXX | 23.34 | 1.57 |
